165 related articles for article (PubMed ID: 20545949)
1. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb.
Yamaguchi M; Harada K; Ando N; Kawamura T; Shibagaki N; Shimada S
Clin Exp Dermatol; 2011 Mar; 36(2):174-7. PubMed ID: 20545949
[TBL] [Abstract][Full Text] [Related]
2. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
3. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
4. Complete response in a melanoma patient treated with imatinib.
Brown MC; Casasola RJ
J Laryngol Otol; 2012 Jun; 126(6):638-40. PubMed ID: 22643209
[TBL] [Abstract][Full Text] [Related]
5. Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC; Bröcker EB; Schadendorf D; Ugurel S
J Clin Oncol; 2007 Mar; 25(7):e9. PubMed ID: 17327598
[No Abstract] [Full Text] [Related]
6. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
7. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
8. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
9. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
10. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
[No Abstract] [Full Text] [Related]
11. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
12. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
13. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
15. Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
[No Abstract] [Full Text] [Related]
16. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
Botella-Estrada R; Soriano V; Rubio L; Nagore E
Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
[No Abstract] [Full Text] [Related]
17. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
Lutzky J; Bauer J; Bastian BC
Pigment Cell Melanoma Res; 2008 Aug; 21(4):492-3. PubMed ID: 18510589
[No Abstract] [Full Text] [Related]
19. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
20. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
